Modeling of the growth kinetics of occult breast tumors: Role in interpretation of studies of prevention and menopausal hormone therapy

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 7, 2012, Pages 1038-1048

  Santen, Richard J ^a   Yue, Wei ^a   Heitjan, Daniel F ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MODEL; CANCER PREVENTION; CONTROLLED STUDY; EARLY INTERVENTION; FEMALE; HEALTH SURVEY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MATHEMATICAL PARAMETERS; MENOPAUSE; PREDICTION; PRIORITY JOURNAL; UNITED STATES;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MENOPAUSE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASMS, HORMONE-DEPENDENT; TAMOXIFEN; UNITED STATES;

EID: 84863602985     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0043     Document Type: Article

References (83)

1. Welch HG, Black WC. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 1997;127:1023-8. (Pubitemid 27516615)
2. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95 Suppl 1:S1-66.
3. Bartow SA, Pathak DR, Black WC, Key CR, Teaf SR. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study. Cancer 1987;60:2751-60. (Pubitemid 17161808)
4. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987;56:814-9. (Pubitemid 18048359)
5. Bhathal PS, Brown RW, Lesueur GC, Russell IS. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer 1985;51:271-8. (Pubitemid 15165083)
6. Khurana KK, Loosmann A, Numann PJ, Khan SA. Prophylactic mastectomy: pathologic findings in high-risk patients. Arch Pathol Lab Med 2000;124:378-81. (Pubitemid 30152138)
7. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975;55:231-73.
8. Alpers CE, Wellings SR. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Hum Pathol 1985;16:796-807. (Pubitemid 15040815)
9. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62. (Pubitemid 41672231)
10. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88. (Pubitemid 28439961)
11. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-92.
12. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53. (Pubitemid 37430077)
13. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573-87.
14. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-14.
15. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. (Pubitemid 34761611)
16. Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57.
17. Gail MH, Mai PL. Comparing breast cancer risk assessment models. J Natl Cancer Inst 2010;102:665-8.
18. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-13.
19. Zahl PH, Maehlen J, Welch HG. The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med 2008;168:2311-6.
20. Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009;339:b2587.
21. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prevent Res 2010;3: 696-706.
22. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial.[Erratum appears in JAMA. 2007 Sep 5;298(9):973].[Erratum appears in JAMA. 2006 Dec 27;296(24):2926]. JAMA 2006;295:2727-41.
23. Goss PE, Ingle JN, es-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91.
24. Berge T, Ostberg G. Bilateral carcinoma of the female breast. Acta Chir Scand 1974;140:27-32.
25. Urban JA. Bilateral breast cancer-biopsy of contralateral breast. Prog Clin Biol Res 1977;12:517-23.
26. Peralta EA, Ellenhorn JD, Wagman LD, Dagis A, Andersen JS, Chu DZ. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 2000;180:439-45. (Pubitemid 32166835)
27. Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 2005;23:4275-86. (Pubitemid 46207002)
28. McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001;19:3938-43. (Pubitemid 32912020)
29. King TA, Gurevich I, Sakr R, Patil S, Stempel M, Morrow M. Occult malignancy in patients undergoing contralateral prophylactic mastectomy. Ann Surg 2011;254:2-7.
30. Arrington AK, Jarosek SL, Virnig BA, Habermann EB, Tuttle TM. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol 2009;16:2697-704.
31. Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV, et al.Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer 2009;115:962-71.
32. Bernard JR Jr, Vallow LA, DePeri ER, McNeil RB, Feigel DG, Amar S, et al.In newly diagnosed breast cancer, screening MRI of the contralateral breast detectsmammographically occult cancer, even in elderly women: the Mayo Clinic in Florida experience. Breast J 2010;16: 118-26.
33. Wanebo HJ, Senofsky GM, Fechner RE, Kaiser D, Lynn S, Paradies J. Bilateral breast cancer. Risk reduction by contralateral biopsy. Annal Surg 1985;201:667-77. (Pubitemid 15019624)
34. Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 2004;101:1977-86. (Pubitemid 39425372)
35. Nielsen M, Christensen L, Andersen J. Contralateral cancerous breast lesions in women with clinical invasive breast carcinoma. Cancer 1986;57:897-903. (Pubitemid 16166136)
36. Ringberg A, Palmer B, Linell F, Rychterova V, Ljungberg O. Bilateral and multifocal breast carcinoma. A clinical and autopsy study with specialemphasis on carcinoma in situ. Eur J Surg Oncol 1991;17:20-9.
37. Leis HP Jr. Managing the remaining breast. Cancer 1980;46 Suppl:1026-30.
38. Beller FK, Nienhaus H, Niedner W, Holzgreve W. Bilateral breast cancer: the frequency of undiagnosed cancers. Am J Obstet Gynecol 1986;155:247-55. (Pubitemid 16054849)
39. Roubidoux MA, Helvie MA, Wilson TE, Lai NE, Paramagul C. Women with breast cancer: histologic findings in the contralateral breast. Radiology 1997;203:691-4. (Pubitemid 27227416)
40. Simkovich AH, Sclafani LM, Masri M, Kinne DW. Role of contralateral breast biopsy in infiltrating lobular cancer. Surgery 1993;114: 555-7. (Pubitemid 23264721)
41. Gutierrez RL, DeMartini WB, Silbergeld JJ, Eby PR, Peacock S, Javid SH, et al. High cancer yield and positive predictive value: outcomes at a center routinely using preoperative breast MRI for staging. AJR Am J Roentgenol 2011;196:W93-9.
42. Lundgren B. Observations on growth rate of breast carcinomas and its possible implications for lead time. Cancer 1977;40:1722-5. (Pubitemid 8220476)
43. von FD, Weber E, Hoeffken W, Bauer M, Kubli F, Barth V. Growth rate of 147 mammary carcinomas. Cancer 1980;45:2198-207.
44. Kusama S, Spratt JS Jr, Donegan WL, Watson FR, Cunningham C. The cross rates of growth of human mammary carcinoma. Cancer 1972;30:594-9.
45. Peer PG, van Dijck JA, Hendriks JH, Holland R, Verbeek AL. Age-dependent growth rate of primary breast cancer. Cancer 1993;71: 3547-51. (Pubitemid 23152663)
46. Tilanus-Linthorst MM, Obdeijn IM, Hop WC, Causer PA, Leach MO, Warner E, et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 2007;13: 7357-62.
47. Tabbane F, Bahi J, Rahal K, el MA, Riahi M, Cammoun M, et al. Inflammatory symptoms in breast cancer. Correlations with growth rate, clinicopathologic variables, and evolution. Cancer 1989;64: 2081-9. (Pubitemid 19280408)
48. Bailey SL, Sigal BM, Plevritis SK. A simulation model investigating the impact of tumor volume doubling time and mammographic tumor detectability on screening outcomes in women aged 40-49 years. J Natl Cancer Inst 2010;102:1263-71.
49. Spratt JS, Meyer JS, Spratt JA. Rates of growth of human neoplasms: Part II. J Surg Oncol 1996;61:68-83. (Pubitemid 26025133)
50. Spratt JA, von FD, Spratt JS, Weber EE. Mammographic assessment of human breast cancer growth and duration. Cancer 1993;71:2020-6. (Pubitemid 23068551)
51. Narod SA. Onbeing the right size: a reappraisal ofmammography trials in Canada and Sweden. Lancet 1997;349:1846. (Pubitemid 27257578)
52. Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, et al. Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. Br Med J 1988;297:943-8.
53. Frisell J, Eklund G, Hellstrom L, Somell A. Analysis of interval breast carcinomas in a randomized screening trial in Stockholm. Breast Cancer Res Treat 1987;9:219-25. (Pubitemid 17135147)
54. Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A. Tumour development, histology and grade of breast cancers: prognosis and progression. Int J Cancer 1996;66:413-9. (Pubitemid 26176764)
55. Vachon CM, Pankratz VS, Scott CG, Maloney SD, Ghosh K, Brandt KR, et al. Longitudinal trends inmammographic percent density and breast cancer risk. Cancer Epidemiol Biomarkers Prevent 2007;16:921-8. (Pubitemid 46910093)
56. Spratt JS, Greenberg RA, Heuser LS. Geometry, growth rates, and duration of cancer and carcinoma in situ of the breast before detection by screening. Cancer Res 1986;46:970-4. (Pubitemid 16145465)
57. Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD. The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr 2006;56-65.
58. Kopans DB, Rafferty E, Georgian-Smith D, Yeh E, D'Alessandro H, Moore R, et al. A simple model of breast carcinoma growth may provide explanations for observations of apparently complex phenomena. Cancer 2003;97:2951-9.
59. Hart D, Shochat E, Agur Z. The growth law of primary breast cancer as inferred from mammography screening trials data. Br J Cancer 1998;78:382-7. (Pubitemid 28336427)
60. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988;48:7067-71. (Pubitemid 19013983)
61. Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971;28:1479-99.
62. Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V, Remington PL. The Wisconsin breast cancer epidemiology simulation model. J Natl Cancer Inst Monogr 2006;37-47.
63. Seer cancer statistics review 2005-2007. Bethesda, MD: National Cancer Institute. [data cited 1997 to 2006]. Available from: http:// seer.cancer.gov/csr/1975-2007/browse-csr.php.
64. Farhat GN, Walker R, Buist DS, Onega T, Kerlikowske K. Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. J Clin Oncol 2010;28: 5140-6.
65. Majed B, Dozol A, Ribassin-Majed L, Senouci K, Asselain B. Increased risk of contralateral breast cancers among overweight and obese women: a time-dependent association. Breast Cancer Res Treat 2011;126:729-38.
66. Robbins GF, Berg JW. Bilateral primary breast cancer; a prospective clinicopathological study. Cancer 1964;17:1501-27.
67. Rosen PP, Groshen S, Kinne DW, Hellman S. Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. Surgery 1989;106:904-10. (Pubitemid 19283388)
68. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 2001;93:1714-23. (Pubitemid 33130260)
69. Song RX, Zhang Z, Mor G, Santen RJ. Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells. Apoptosis 2005;10:667-78. (Pubitemid 40896672)
70. Song RX, Santen RJ. Apoptotic action of estrogen. Apoptosis 2003;8:55-60. (Pubitemid 36133138)
71. Hu ZZ, Kagan BL, Ariazi EA, Rosenthal DS, Zhang L, Li JV, et al. Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells. PLoS One 2011;6: e20410.
72. Jordan VC, Ford LG. Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis. Cancer Prevent Res 2011;4:633-7.
73. Lewis-Wambi JS, Jordan VC. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 2009; 11:206.
74. Lewis-Wambi JS, Swaby R, Kim H, Jordan VC. Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer. J Steroid Biochem Mol Biol 2009;114:33-9.
75. Swaby RF, Jordan VC. Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin Breast Cancer 2008;8:124-33. (Pubitemid 351655926)
76. Jordan VC. The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer-survival or death? J Clin Oncol 2008;26:3073-82.
77. Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 2005;97: 1746-59. (Pubitemid 41782284)
78. Santen RJ. The breast: lactation and breast cancers as an endocrine disease, pp. 1305-1318. In Wass JAH, Stewart PM, editors. Oxford textbook of endocrinology. 2011.
79. Amir E, Freedman OC, Seruga B, Evans DG. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst 2010;102:680-91.
80. Xu J, Kochanek MA, Murphy SL, Tejada-Vera BS. Deaths: final data for 2007. Natl Vital Stat Rep 2011;58.
81. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 2005; 20:2052-60. (Pubitemid 41418488)
82. Santen RJ. Does menopausal hormone therapy initiate new breast cancers or promote the growth of existing ones? Women Health 2008;4:207-10. (Pubitemid 351781155)
83. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001;28: 400-18. (Pubitemid 32762083)